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1358Objective: There has been considerable improvement in survival after the first stage of palliation for single-
ventricle heart disease. Yet, interstage mortality continues to plague this population. Home monitoring has
been proposed to reduce interstage mortality. We review our experience after creation of a Single Ventricle
Program.
Methods: All infants with a single ventricle heart defect who were admitted to Texas Children’s Hospital from
the inception of the Single Ventricle Program on September 1, 2007, to January 1, 2010, were included in the
Single Ventricle Program cohort. Infants with a single ventricle presenting between January 1, 2002, and August
31, 2007, comprised the pre-Single Ventricle Program group. Anatomic, operative, and postoperative details
were noted for all patients. End points included in-hospital death after the first stage of palliation, interstage
death (defined as after discharge from the first stage of palliation and before the second stage of palliation),
and death or heart transplantation by 1 year of age. Interstage weight gain was also compared.
Results: A total of 137 infants with a single ventricle were included in the pre-Single Ventricle Program cohort,
and 93 infants were included in the Single Ventricle Program cohort. Anatomic subtypes were similar between
groups. There was significant improvement in rate of interstage weight gain, whereas age at the second stage of
palliation was significantly reduced in the Single Ventricle Program group. In-house mortality decreased during
the Single Ventricle Program era (P ¼ .021). Interstage mortality did not significantly decrease in the Single
Ventricle Program group. However, 1-year transplant-free survival improved during the Single Ventricle Pro-
gram era (P ¼ .002).
Conclusions: The Single Ventricle Program improved interstageweight gain, thereby allowing for early second-
stage palliation at an equivalent patient weight. Interstage mortality was not significantly reduced by our pro-
gram. However, 1-year transplant-free survival was significantly improved in patients in the Single Ventricle
Program. (J Thorac Cardiovasc Surg 2011;142:1358-66)Operative survival after stage 1 surgical palliation (S1P) for
single-ventricle heart disease has improved significantly
over the past 2 decades.1-3 This improvement is thought
to be due to earlier detection and diagnosis of single-
ventricle heart disease, improved pre- and postoperative
management strategies, and refinements in surgical tech-
nique. Nonetheless, interstage mortality—death after dis-
charge from S1P and before stage 2 surgical palliation
(S2P) —persists at rates varying from 5% to 19%.4-6
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The Journal of Thoracic and Cardiovascular Surunknown, although thrombosis of the systemic-to-
pulmonary artery shunt and arrhythmia are believed to be
significant contributors to interstage mortality.
The results of an intensive home-monitoring program,
which included home pulse-oximetry, daily weight checks,
and close clinic follow-up, were reported recently.7 This re-
port demonstrated a significant improvement in interstage
mortality. There were no early postoperative deaths or inter-
stage deaths (IDs) noted during the study period. One aspect
proposed in this report was earlier timing of S2P, thus reduc-
ing the length of the interstage period. It remained unclear
whether these results would be generalizable to other insti-
tutions with more diverse populations. It was also unclear
whether reduction in ID was simply a reflection of a shorter
interstage period, while the overall mortality at 1 year
would remain unchanged. Nevertheless, this report has
prompted many centers to consider the creation of dedi-
cated outpatient programs to monitor infants with single-
ventricle heart disease. We report on our early experience
after creation of a dedicated Single Ventricle Program
(SVP), which includes both home monitoring—pulsegery c December 2011
Abbreviations and Acronyms
BT ¼ Blalock–Taussig
CAVC ¼ complete atrioventricular canal
DORV ¼ double-outlet right ventricle
G-tube ¼ gastrostomy tube
HLHS ¼ hypoplastic left heart syndrome
ID ¼ interstage death
RVPA ¼ right ventricle-to-pulmonary artery
S1P ¼ stage 1 surgical palliation
S2P ¼ stage 2 surgical palliation
SVP ¼ Single Ventricle Program
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Doximetry and daily weight checks—and access to a dedi-
cated physician and nurse practitioner team who maintain
close outpatient contact with our infants with a single ven-
tricle awaiting S2P.We describe our experience since the in-
ception of our program and compare interstage mortality,
patient weight gain, and 1-year mortality before and after
the program was initiated.MATERIALS AND METHODS
Patient Characteristics
All patients with single-ventricle anatomy from January 1, 2002, to Feb-
ruary 1, 2010, were included in this study. Patient data were attained after
a careful review of both the cardiac surgical and the cardiology patient da-
tabases. Patients enrolled in the SVP had multiple anatomic subtypes of
single ventricle, including hypoplastic left heart syndrome (HLHS), unbal-
anced complete atrioventricular canal (CAVC), tricuspid atresia, double-
inlet left ventricle, and double-outlet right ventricle (DORV) with mitral
atresia/stenosis. Not all patients underwent Norwood-type palliation at
the initial neonatal surgery. Accordingly, the comparison groups, drawn
from the period between January 1, 2002, and August 31, 2007, included
all patients with the same range of diagnoses.
Patient characteristics, including birth weight, gestational age, age and
weight at S1P, and associated genetic lesions, were noted. Details of S1P
were also noted, including need for pulmonary vein or atrioventricular
valve repair, type of pulmonary blood flow source at S1P (modified Bla-
lock–Taussig [BT] shunt or right ventricle-to-pulmonary artery [RVPA]
conduit), and time to discharge from S1P. Nutritional details were reviewed
from both the time of discharge from S1P and the interstage period; such
details included route of enteral feeding (oral vs nasogastric or gastrostomy
tube [G-tube]), formula calorie content, and patient weight at time of birth,
S1P, discharge from S1P, and S2P.
Mortality details were carefully reviewed for all patients. Mortality at
any point within the first year of life was noted. In-hospital mortality
was defined as death after S1P and before discharge. Interstage mortality
was defined as death after discharge from S1P and before S2P. One-year
mortality was also reviewed, and all deaths (in-hospital, interstage, and
post-S2P death) were included in this review. One-year mortality also in-
cluded those patients with a single ventricle who underwent heart trans-
plantation within the first year of life.
Single Ventricle Program
The SVP began on September 1, 2007, at Texas Children’s Hospital. As
noted above, patients with many various anatomic subtypes of single ven-
tricle are included. The goal of the program has been to optimize nutritionThe Journal of Thoracic and Carandmedical management, and to reduce ID among all patients with a single
ventricle. The SVP is composed of 6 pediatric cardiologists, 6 nurse prac-
titioners, a social worker, a nutritionist, and a developmental pediatrician,
all of whom participate in the SVP in addition to their primary heart center
responsibilities. Parents of all patients with a single ventricle are prospec-
tively approached and consented for enrollment into the SVP at the time of
initial presentation in the neonatal period. All pertinent patient variables—
demographics, single ventricle type, patient size/age at S1P, type of S1P,
and associated noncardiac problems—are included in our SVP database.
Operative variables evaluated include type of S1P performed, placement
of a systemic-to-pulmonary artery (modified BT shunt) or a ventriculo-
pulmonary (RVPA) conduit, need for atrioventricular valve repair or pul-
monary vein repair, and other associated surgical interventions. Patients
are officially enrolled into the SVP on discharge from S1P and are dis-
charged from SVP after their first outpatient visit after S2P.
Members of the SVP meet with the parents on a number of occasions
before discharge from S1P. In particular, when there are protracted difficul-
ties with oral feeds, the SVP may recommend G-tube placement. This rec-
ommendation is only made after a thorough evaluation by our feeding team
and speech therapists. The recommendation for G-tube is made with input
from the inpatient and surgical teams, and the parents.
Patients are seen in the designated SVP outpatient clinic located within
the hospital. The frequency of outpatient visits is determined by a number
of factors, including patient age, medical status, and nutritional status. The
nurse practitioners maintain at least weekly telephone contact with all SVP
families during the interstage period. Decreased oxygenation (pulse-
oximetry< 75%) or failure to gain weight on at least 3 successive days
may prompt an outpatient visit or inpatient admission. Weekly meetings
of the SVP team are held to discuss each interstage patient and to formulate
his/her medical plan, including the pre-S2P evaluation and timing of S2P.
The SVP team attempted not only to attain a close partnership with each
family during the interstage period but also to achieve a consistency in
the medical and nutritional management of patients with a single ventricle.
Consistency in the timing of S2Pwas thought to be critically important, and
patients were routinely scheduled to undergo S2P between 4 and 5 months
of age provided they were growing well and were thought to be good can-
didates for promotion to cavopulmonary physiology.Statistical Analysis
Data are expressed as mean  standard deviation or median (range)
where appropriate. Characteristics of the pre-SVP and SVP cohorts were
compared using nonpaired t test and Fisher exact test where appropriate.
We sought to determine the incidence of the following clinical end points:
(1) in-hospital death after S1P, (2) ID, and (3) death or transplant at 1 year.
For in-hospital death and 1-year survival end points, we compared patients
by era (pre-SVP era vs SVP era) rather than by SVP enrollment, because
patients who died before discharge from S1P were not enrolled in the
SVP. For ID comparisons, SVP enrollment was evaluated. We compared
the rates of the above end points between the pre-SVP and SVP cohorts us-
ing Kaplan–Meier analysis. For time-dependent end points, Cox multivar-
iate analysis was performed to identify factors associatedwith development
of those outcomes. For 1-year mortality comparison, binary logistic regres-
sion was performed to identify risk factors. We also compared patient
weight at time of S1P, discharge fromS1P, and discharge fromS2P between
the pre-SVP and SVP cohorts. Weight-for-age z scores were calculated
using the Anthro (Version 3.1) calculator provided by the World Health
Organization. Rate of weight gain during the interstage period and
weight-for-age z scores were compared using a standard nonpaired t test.
Finally, the same analyses listed abovewereperformed for the subgroupof
patients with a single ventricle associated with systemic outflow obstruction
(HLHS, DORV/mitral atresia, and unbalanced CAVC) who underwent
Norwood-type palliation at S1P. For theNorwood subgroup, comparisons be-
tween SVP and pre-SVP cohorts were made. Further, comparison between
Norwood types (aortopulmonary shunt versus ventriculo-pulmonaryconduit)diovascular Surgery c Volume 142, Number 6 1359








Birth weight (kg) 3.05  0.50 3.08  0.50 .67
Gestational age (wk) 38.2  1.5 38.4  1.4 .44
Age at S1P (d) 13.8  12.4 8.5  6.6 .01
Weight at S1P (kg) 3.17  0.66 3.09  0.51 .36
Diagnoses
HLHS 82 (59.8%) 49 (55.7%) .28
Unbalanced CAVC 43 (31.4%) 23 (26.1%) .45
DILV 5 (3.6%) 2 (2.3%) .71
Heterotaxy syndrome 36 (26.3%) 17 (19.3%) .36
S1P operative characteristics
BT shunt 110 (80.3%) 56 (63.6%) .02
RVPA conduit 1 (0.7%) 21 (23.9%) .01
PA banding 29 (21.2%) 11 (12.5%) .16
Pulmonary vein repair 19 (13.9%) 8 (9.1) .38
Atrioventricular valve repair 3 (2.1%) 8 (9.1%) .03
Interstage characteristics
Age at D/C from S1P (d) 43.8  30.6 37.5  19.3 .07
Weight at D/C from S1P (kg) 3.4  0.7 3.5  0.7 .17
Weight at S2P (kg) 6.5  1.8 6.3  1.2 .29
Weight-for-age z score at S1P 1.08  1.30 0.95  1.14 .43
Weight-for-age z score at S2P 1.84  1.53 1.38  1.27 .03
Age at S2P (d) 221.4  112.2 157.6  49.4 <.01
Daily weight gain from S1P
to S2P (g/d)
19.8  8.4 23.6  7.9 <.01
Outpatient clinic frequency
(visits/30 d)
1.1  1.0 1.5  0.7 <.01
ED encounter frequency
(visits/30 d)
0.1  0.3 0.1  0.2 .78
Unplanned admissions
(admits/30 d)




21.8  2.8 23.8  2.0 <.01
PO feeding at D/C from
S1P (%)
87 (75%) 73 (83%) .03
NG-tube dependency from
S1P-S2P (%)
18 (16%) 5 (6%) .06
G-tube dependency from
S1P-S2P (%)
8 (7%) 13 (15%) .03
S2P operative details














In-hospital death after S1P
(predischarge)
21 (15%) 4 (4%) <.01
ID 14 (12%) 7 (8%) .49
Cause of ID
Sudden/unknown cause 10 4 NS






35 (26%) 11 (12%) .01
1-y transplant-free survival 97 (71%) 78 (84%) .02
Pre-SVP, Infants who underwent S1P before SVP inception; SVP, infants who under-
went S1P during SVP and who enrolled in the program; D/C, discharge; LOS, length
of stay; DILV, double-inlet left ventricle; PA, pulmonary artery; ED, emergency de-
partment; PO, oral; NG, nasogastric.
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statistical analysis, SPSS version 18 was used (SPSS Inc, Chicago, Ill).
RESULTS
A total of 230 infants with various forms of single ventri-
cle underwent S1P at Texas Children’s Hospital between
January 1, 2002, and December 30, 2009. Of this total,
137 patients underwent S1P pre-SVP (January 2002 to1360 The Journal of Thoracic and Cardiovascular SurAugust 2007), and 93 infants underwent S1P during the
SVP era (September 2007 to February 2010). One patient
who underwent S1P during the SVP period did not enroll
in the SVP because of out-of-state residency, and 4 patients
during the SVP era died in-hospital before discharge from
S1P and were therefore not enrolled in the SVP. Thus, al-
though there were 93 patients who underwent S1P during
the SVP era, the SVP enrollment cohort included 88 pa-
tients. The most common diagnosis for both groups was
HLHS, followed by right-dominant CAVC defect (Table
1). Therewere no significant differences in prevalence of di-
agnoses between the pre-SVP and SVP groups.
Timing of S1P was earlier in the SVP group, who under-
went initial palliation at 8.3  6.5 days of life, compared
with 13.8  12.4 days of life in the pre-SVP group
(P ¼ .03). Components of the S1P between both groups
are detailed in Table 1. There were no differences in rates
of heterotaxy syndrome, pulmonary vein repair, or atrioven-
tricular valve repair at S1P between the pre-SVP and SVP
groups. However, use of the RVPA conduit increased
from 1 of 137 infants in the pre-SVP era to 21 of 93 infants
in the SVP era. This change was due to individual surgeon
preference and did not reflect a program-wide change. Be-
cause some patients, particularly thosewith tricuspid atresia
or double-inlet left ventricle, presented with congestive
heart failure rather than systemic arterial obstruction, pul-
monary artery banding was occasionally used during S1P,
and the Damus–Kaye–Stansel reconstruction or palliative
arterial switch was deferred in these patients until S2P. Pa-
tients in both the SVP and pre-SVP cohorts were similar in
age and weight at time of discharge from S1P (Table 1).Interstage Period
The SVP cohort was observed more frequently during the
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FIGURE 1. Interstage weight gain in the SVP group outpaced the growth
rate in the pre-SVP group. The SVP group was promoted to S2P at an ear-
lier age and yet had achieved a similar weight at an earlier time compared
with the pre-SVP group. SVP, Single Ventricle Program; S1P, stage 1 pal-
liation; S2P, stage 2 palliation.
TABLE 2. Multivariate analyses
Risk factor Hazard ratio (95% CI) P value
In-hospital death (post-S1P)
Age at S1P>14 d 3.41 (1.2–11.4) .046
Weight at S1P (kg) 0.69 (0.3–1.4) .315
HLHS 1.11 (0.41–3.0) .833
BT shunt at S1P 3.12 (1.5–5.9) .012
AV valve repair at S1P 1.0 (0.9–11.1) .889
SVP era 0.258 (0.1–0.8) .024
ID
HLHS 10.9 (2.2–53) .016
Higher weight at S1P (kg) 0.33 (0.1–0.8) .015
BT shunt at S1P 0.53 (0.1–1.9) .341
AV valve repair at S1P 7.4 (1.0–54) .069
SVP member 1.06 (0.3–3.4) .924
Death or transplant at 1 y
Single RV 1.24 (0.1–16) .871
Pre-SVP era 6.96 (1.2–52) .049
Age at S2P (d) 0.01 (0.00–0.02) .001
BT shunt at S1P 8.76 (1.6–67) .037
Death or transplant at 1 y, Norwood cohort
Pre-SVP era 2.13 (1.1–5.6) .031
Age at S1P (d) 1.10 (1.1–1.2) .043
Weight at S1P (kg) 0.41 (0.1–0.8) .029
BT shunt at S1P 1.20 (0.3–4.3) .783
AV, Atrioventricular; SVP era, pre-SVP era for infants who underwent S1P before
September 1, 2007, post-SVP era for infants who underwent S1P after September
1, 2007; single RV, single-ventricle type with morphologic right ventricle.
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Dvisits per patient per 30 days for the SVP cohort, compared
with 0.99  1.12 visits per patient per 30 days for pre-SVP
patients (P< .01). Rates of unplanned admissions to the
hospital and emergency department visits did not differ be-
tween the groups (Table 1). Patients enrolled in the SVP
were more likely to receive fortified formula, with an aver-
age caloric content of 23.9  2.0 calories/ounce, compared
with 21.8  2.8 calories/ounce in the pre-SVP group
(P¼ .021). SVP patients were more likely to be completely
orally fed at the time of discharge from S1P, where only
12.2% required tube feed supplementation, compared
with 27.3% of patients in the pre-SVP group (P ¼ .004).
However, when tube supplementation was required, there
was a higher rate of G-tube use in the SVP group
(P ¼ .016) and a higher rate of nasogastric tube use in the
pre-SVP group (P ¼ .003).
Timing of S2P differed significantly between the pre-
SVP cohort (210  114 days) and the SVP cohort (159 
52 days) (P<.001). The variation in timing was reduced
as well, from a standard deviation of  114 days for the
pre-SVP group to 52.4 days for the SVP group. Although
weight-for-age z score did not differ between the eras at
S1P, the SVP group had a higher weight-for-age z score
of1.38  1.27 compared with1.84  1.53 for the pre-
SVP group at S2P (P ¼ .029). The average patient weight
at S2P was 6.35  1.23 kg for the SVP group compared
with 6.36 1.49 for the pre-SVP group (P¼NS). Thus, av-
erage daily weight gain was greater in the SVP group at 22.5
 6.1 g/d compared with 17.9  6.6 g/d for the pre-SVP
group (P ¼ .01) (Figure 1).
Before discharge from S1P, 21 of 137 infants (15.3%) in
the pre-SVP cohort died, whereas 4 of 93 infants (4.5%) in
the SVP era died (P ¼ .021). Binary logistic regressionThe Journal of Thoracic and Carrevealed that age more than 14 days at S1P (P ¼ .046),
S1P with a BT shunt (P ¼ .012), and S1P during the pre-
SVP era (P¼ .024) were associated with predischarge mor-
tality (Table 2).
There were 14 cases of ID in the pre-SVP group (12.1%)
and 7 cases of ID in the SVP group (8.3%) (P¼ .924). Cox
regression analysis demonstrated that low weight at S1P
(P ¼ .043) and diagnosis of HLHS (P ¼ .010) were associ-
ated with increased risk of ID (Table 2). No association was
found between ID and pulmonary vein repair, atrioventric-
ular valve repair, or the additional diagnosis of heterotaxy
syndrome. An autopsy was performed in 10 of 21 patients
who experienced ID and demonstrated BT shunt thrombosis
in 4 patients, whereas no cause was found in 6 patients. The
majority of ID cases (14/21) were sudden and unexpected
deaths of unknown cause (Table 2). HLHS was the diagno-
sis in 19 of 21 patients (90%) with ID. When evaluated col-
lectively, pre-S2P mortality, defined as either in-hospital or
post-discharge death after S1P, was higher in the pre-SVP
era (P ¼ .003) and in patients with the diagnosis of
HLHS (P ¼ .001) (Figure 2).
One-Year Survival
At 1 year of age, 55 of 230 patients had died (n ¼ 52) or
undergone heart transplantation (n¼ 3), giving a 1-year sur-
vival of 76.3% for the entire cohort (Figure 3). Attrition oc-
curred primarily before S2P (46/55, 84%) (Figure 4). Therediovascular Surgery c Volume 142, Number 6 1361
FIGURE 2. Kaplan–Meier analysis of survival between S1P and S2P.
Both in-hospital death after S1P and ID are included in the mortality for
these analyses. A, Survival between the SVP and the pre-SVP cohorts is
compared. The SVP cohort has a lower rate of in-hospital and ID. B,
Among the entire cohort, patients with HLHS are at higher risk for pre-
S2P mortality when they are compared with the remainder of the cohort.
SVP, Single Ventricle Program; S1P, stage 1 palliation; S2P, stage 2 palli-
ation; HLHS, hypoplastic left heart syndrome.
FIGURE 3. Kaplan–Meier analysis of 1-year transplant-free survival. A,
Among the entire single-ventricle cohort (both SVP and pre-SVP), the
1-year transplant-free survival is 76.3%. The majority of events occur
before 0.3 years. B, There is improvement in 1-year transplant-free survival
in the SVP cohort. SVP, Single Ventricle Program.
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era in 78 of 93 patients (83.8%) compared with the pre-SVP
era in 97 of 137 patients (70.8%) (P¼ .002). Binary logistic
regression analysis demonstrated that pre-SVP era
(P ¼ .019) and low weight at S1P (P ¼ .026) were associ-
ated with 1-year mortality/transplantation (Table 2).Norwood Cohort
Of the 230 patients, 151 (66%) underwent Norwood-type
palliation at S1P, of whom 87 (58%) were pre-SVP and 641362 The Journal of Thoracic and Cardiovascular Sur(42%) were SVP members. The most common diagnoses
among this subgroup were HLHS (80%), unbalanced
CAVC (15%), and DORV/mitral atresia (4%). A total of
22 patients (15%) underwent RVPA conduit with a Nor-
wood procedure, with the remaining patients having a BT
shunt; as noted above, 21 of 22 (96%) RVPA Norwood pro-
cedures were performed during the SVP era (P<.01). Pre-
discharge mortality after S1P was 14 of 87 (16.1%) during
the pre-SVP era and 4 of 64 (6.2%) during the SVP era
(P¼ .065). ID occurred in 10 patients in the pre-SVP cohort
(13.7%) and in 4 patients (7.1%) in the SVP cohort
(P ¼ .28). Multivariate regression analysis revealed that
among the Norwood cohort, placement of a BT shunt
(P ¼ .04) and low patient weight at S1P (P ¼ .03) were as-
sociated with ID, whereas membership in the SVP was not
protective against ID (P ¼ .94).
By 1 year, 30 of 87 (34.4%) of the pre-SVP Norwood co-
hort had undergone heart transplantation (n ¼ 2) or died
(n ¼ 28). In the SVP Norwood cohort, 15 of 64 patients
(23.4%) underwent heart transplantation (n ¼ 1) or died
(n ¼ 14) by 1 year of age (Figure 5). Binary logisticgery c December 2011





















FIGURE 4. Timeline of mortality events (death or heart transplantation)
in pre-SVP (dark grey) and SVP (light grey) groups. The timeline demon-
strates that the majority of events occurred early (<0.4 years). SVP, Single
Ventricle Program.
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group, higher weight at S1P (P ¼ .045), younger age at
S1P (P ¼ .033), and SVP era (P ¼ .031) were associated
with improved 1-year transplant-free survival (Table 2).
Pulmonary blood flow source type was not associated
with 1-year transplant free survival (Figure 5, B).DISCUSSION
Over the past 2 decades, there has been adoption of a more
or less uniform staged palliative approach to the patient with
single-ventricle anatomy. Survival after S1P continues to im-
prove since the inception of the Norwood operation.1-3 A
significant effort has been taken by a number of academic
centers to identify risk factors that relate to mortality, both
before initial stage palliation and between stages. These
efforts have resulted in a collective improvement, among
a number of centers, in outcomes for infants with single-
ventricle anatomy.8-10 The commonly accepted reasons for
improved outcomes include technical advancements and
modifications associated with S1P, earlier detection of
heart disease, and improvements in preoperative and
postoperative care of neonates after S1P reconstruction.3,11
The impact of close outpatient surveillance remains unclear.
In our retrospective analysis, we found that mortality be-
fore S2P continues to be an important problem in patients
with single-ventricle anatomy.Although early postoperative
mortality was reduced during the SVP era, interstageThe Journal of Thoracic and Carmortality did not significantly decrease. Although postoper-
ative management continues to evolve at Texas Children’s
Hospital, there was no identifiable shift in the pre- and post-
operative medical management that could account for the
decrease in predischarge mortality. Surgical management
of these patients did evolve over this time period: RVPA
conduit use increased during the SVP era, and this had a de-
monstrable effect on predischarge survival. We believe that
earlier timing of S1P also played a large role in the reduction
in predischarge mortality. During the SVP era at Texas
Children’s Hospital, patients underwent S1P at an earlier
age secondary to multiple factors: expansion of the cardiac
intensive care unit and operating rooms, and a greater impe-
tus toward earlier surgery. A number of studies have demon-
strated that delay beyond 7 to 14 days of age for S1P is
associated with mortality.2,4
It was disappointing that the interstage mortality did not
decrease after initiation of a comprehensive outpatient pro-
gram at Texas Children’s Hospital, given the published
data from other centers.7,12 In the report by Ghanayem and
colleagues,7 interstage mortality was eliminated with the
use of outpatient home pulse-oximetry and daily weight
monitoring after S1P. These infants were put forward for
S2P at less than 5 months of age. The patients reported by
Ghanayem and colleagues were often followed by cardiolo-
gists outside of the primary institution. The experience at the
Children’s Hospital of Wisconsin had a large impact on the
formation of our program.However, in contrast with the pro-
gram described in their report, all patients in our SVP were
followed primarily by the designated SVP clinicians. In ad-
dition, before discharge from S1P all patients in our SVP had
rhythm monitoring and airway and feeding evaluations to
carefully identify those patients known to be at highest risk
for ID. Nonetheless, interstage mortality continued at
a rate of 8.3%, despite close outpatient follow-up and
home monitoring.
The causes of interstage mortality have been extensively
studied. Simsic and colleagues5 described a higher rate of
postoperative arrhythmia in infants who experienced ID.
Mahle and colleagues13 reviewed an extensive variety of
preoperative and perioperative factors and found that only
earlier era of S1P and history of arrhythmia were associated
with ID. Likewise, Hehir and colleagues4 noted that the ma-
jority of IDs were sudden, unexpected events in infants with
a history of arrhythmia. Thus, even with vigilant outpatient
monitoring of at-risk infants with a single ventricle, there
may be a limited ability to reduce interstage mortality. In-
deed, although outpatient pulse-oximetry may act as a reli-
able screening tool for shunt thrombosis or stenosis, it
seems that many instances of ID are not associated with
shunt occlusion. In a multi-institutional study by Li and col-
leagues,14 the mortality rate after Norwood palliation in
infants exceeded the rate of thrombosis within systemic-
to-pulmonary shunts. The authors postulated that coronarydiovascular Surgery c Volume 142, Number 6 1363
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It does seem that the Norwood circulation, in particular, of-
ten results in a tenuous balance among the systemic, pulmo-
nary, and coronary circulation. Thus, it is likely that no tool
currently available can reliably screen for and prevent all in-
stances of sudden ID.
Earlier timing of S2P has been proffered as a means to re-
duce interstage mortality. Although some reports have indi-
cated poorer outcomes associated with S2P at less than 4
months of age, others have indicated that earlier S2P is
safe.15-17 In our experience with the SVP, patients were
brought forward for S2P as early as 3 months of age and
were rarely held for more than 5 months before S2P. To
study the efficacy of such a strategy, we thought it
important to review the 1-year mortality of the SVP group.
We note that there is a significant improvement in 1-year
transplant-free survival during the SVP era. Yet, most attri-
tion occurred pre-S2P, and although in-hospital mortality
was lower during the SVP era, interstage mortality was
not significantly reduced. Thus, improved 1-year survival
may be secondary to other factors, including earlier promo-
tion to S1P in neonates with single-ventricle anatomy.
The most significant reduction in mortality was seen be-
fore discharge from S1P. Both earlier age at S1P and the
limited use of the RVPA conduit were found to be protective
against early in-hospital mortality. However, there was little
attrition after S2P in either the pre-SVP or SVP era, indicat-
ing that the benefits, if any, of early promotion to cavopul-
monary circulation cannot be appreciated by 1 year of age.
Patient growth during the interstage period is a crucial
factor in allowing for early S2P surgery, and studies have
shown that weight gain in infants with a single ventricle is
particularly challenging.18,19 The study by Kelleher and
colleagues20 demonstrated that somatic growth is restricted
in patients with a single ventricle, particularly in the
interstage period. Their report demonstrated that low
weight-for-age z score was associated with poorer outcomes,
including more frequent interstage admissions. Low patient
weight at S2P has also been associated with longer inpatient
stay, longer duration of pleural drainage, and longer duration
of mechanical ventilation.17 The study by Hsu and col-
leagues21 demonstrated that the mean weight-for-age z score
at the time of S2P was1.6, and the z score average remained
below zerowell beyond S2P. Cognizant of the risks of S2P in
growth-restricted infants, we used a nutritionist and feedingFIGURE 5. Kaplan–Meier analysis of 1-year transplant-free survival in
the subgroup of patients with a single ventricle who underwent
Norwood-type palliation at S1P. A, The SVP cohort experienced improved
1-year transplant-free survival. B, There is no statistically significant im-
provement in 1-year transplant-free survival with the modified Norwood
with RVPA conduit. C, BT shunt group appears to have improved survival
at 1 year, but this difference in survival fails to reach statistical significance.
SVP, Single Ventricle Program; BT, Blalock–Taussig.
:
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Dteam to optimize caloric delivery in the interstage period.
Patient growth was improved with this approach, and by
the time of S2P, patients had achieved a higher weight-for-
age z score than their predecessors in the pre-SVP era.
Thus, the SVP patients were able to attain an equivalent
weight to the pre-SVP group in a shorter period of time,
which allowed them to undergo S2P at equivalent size but
at a younger age. Indeed, the rate of recovery and time to dis-
charge from S2P were the same between the 2 groups, indi-
cating that the SVP group underwent earlier S2P at no
additional risk. Aside from the nutritional and growth benefits
attained by this approach, it remains uncertain what other
benefits will be derived from the earlier S2P itself.
Texas Children’s Hospital is somewhat unique in its lim-
ited adoption of the RVPA conduit at S1P. There is a signif-
icant body of literature supporting the early benefits of
RVPA conduit use in neonates with single-ventricle anat-
omy.9,10,22 Since Sano and colleagues23 reported their expe-
rience with the RVPA conduit, many centers have
reproduced the improved interstage survival at a cost of ear-
lier S2P because of decreased systemic oxygen satura-
tions.24-26 Indeed, a recent multicenter randomized study
indicated a significantly improved 12-month survival with
use of the RVPA conduit.22 In our center’s experience, we
did find that in comparison with the RVPA conduit group,
the BT shunt group had a higher rate of early, in-hospital
death, and a higher rate of ID among the HLHS cohort. In-
deed, the difference in 1-year transplant-free survival be-
tween the RVPA conduit group and the BT shunt group
did not reach statistical significance in our study. Neverthe-
less, our data support the use of the RVPA conduit at S1P,
and it may be particularly useful in low-birthweight
neonates.
This report differs from other published reports in that
our SVP enrolled infants with a wide range of single-
ventricle heart disease, including patients without systemic
outflow obstruction and patients with single, morphologic
left ventricles. However, this heterogeneity reflects the pop-
ulation served at Texas Children’s Hospital. Of course, at
Texas Children’s Hospital, infants who underwent Nor-
wood palliation also had improved survival at 1 year of
age. That outcomes improved in a heterogeneous popula-
tion with single-ventricle anatomy after initiation of the
dedicated program suggests that these results are generaliz-
able and reproducible at other centers.
This study had a number of limitations, including its ret-
rospective nature. The heterogenous nature of our cohort
made it difficult to control for a number of factors, particu-
larly in the more complex heterotaxy population. The
higher incidence of early mortality in the pre-SVP group
may have affected the 1-year survival significantly; thus,
reduction in early mortality before the intensive home
monitoring certainly played a large role in improvement
in 1-year survival.The Journal of Thoracic and CarCONCLUSIONS
Since the initiation of the SVP at Texas Children’s
Hospital, there has been a significant reduction in early
in-hospital mortality and improved interstage growth. Al-
though the SVP did not succeed in reducing interstage mor-
tality, the 1-year transplant-free survival was significantly
improved during the SVP era. This may reflect the success
of a strategy that included earlier promotion to S1P and op-
timizing interstage weight gain, with subsequent earlier
second-stage surgical palliation.
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